'A big reason Icahn feels $CI is paying too much for $ESRX, @CaraRLombardo and @DanaMattioli write, is Trump administration efforts "to limit the manufacturer rebates pharmacy-benefit managers receive."'-WSJ's Jonathan Rockoff Tweets